Skip to main content

Table 2 Proportion of serotypablea lytA-positive samples (n = 607) by lytA cycle threshold value (Ct-value) among patients hospitalized with severe acute respiratory illness at Chris Hani-Baragwanath Academic Hospital, Soweto, South Africa, 2009–2012

From: Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa

lytA Ct-value Serotypablea lytA-positive samples
n/N (%) OR (95 % CI) p
≤30 54/71 (76.1) Reference -
31 20/23 (86.9) 2.1 (0.6-7.9) 0.275
32 22/28 (78.6) 1.2 (0.4-3.3) 0.790
33 32/36 (88.9) 2.5 (0.8-8.1) 0.123
34 28/42 (66.7) 0.6 (0.3-1.5) 0.281
35 31/57 (54.4) 0.4 (0.2-0.8) 0.011
36 29/72 (40.3) 0.2 (0.1-0.4) <0.001
37 28/93 (30.1) 0.1 (0.07-0.3) <0.001
38 27/134 (20.1) 0.08 (0.04-0.15) <0.001
39 8/51 (15.7) 0.06 (0.02-0.14) <0.001
  1. Abbreviations: OR: odds ratio; CI: confidence interval
  2. aSerotypable samples were samples tested with the serotyping assay from which a serotype/serogroup included in the assay was detected